Ravidasvir

Ravidasvir
Clinical data
Synonyms	PPI-668
ATC code	None;
Identifiers
	IUPAC name (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one;
CAS Number	1242087-93-9;
PubChem CID	52918888;
ChemSpider	31141686;
UNII	AL3G001BI8;
ChEMBL	CHEMBL3121849;
Chemical and physical data
Formula	C42H50N8O6
Molar mass	762.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1; Key:LCHMHYPWGWYXEL-ZYADHFCISA-N;

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.^[1]

Preliminary clinical trial results were announced in Nov 2015.^[2]. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.^[3]. These trials were supported by the Drugs for Neglected Diseases initiative and funded by the charity Médecins Sans Frontières.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

[2] Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4

[3] Julia Kollewe, "Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative", The Guardian, 13th April 2018

Ravidasvir

See also

References